Results 61 to 70 of about 560,370 (324)

The power of microRNA regulation—insights into immunity and metabolism

FEBS Letters, EarlyView.
MicroRNAs are emerging as crucial regulators at the intersection of metabolism and immunity. This review examines how miRNAs coordinate glucose and lipid metabolism while simultaneously modulating T‐cell development and immune responses. Moreover, it highlights how cutting‐edge artificial intelligence applications can identify miRNA biomarkers ...
Stefania Oliveto, Nicola Manfrini, Stefano Biffo   +2 more
wiley   +1 more source

Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy

Journal of Hematology & Oncology
Cancer immunotherapy and vaccine development have significantly improved the fight against cancers. Despite these advancements, challenges remain, particularly in the clinical delivery of immunomodulatory compounds.
Qiang Lu, Dongquan Kou, Shenghan Lou, M. Ashrafizadeh, A. Aref, Israel Cañadas, Yu Tian, Xiaojia Niu, Yuzhuo Wang, Pedram Torabian, Lingzhi Wang, Gautam Sethi, Vinay Tergaonkar, Franklin Tay, Zhennan Yuan, Peng Han   +15 more
semanticscholar   +1 more source

CAR T cell immunotherapy for human cancer

Science, 2018
Adoptive T cell transfer (ACT) is a new area of transfusion medicine involving the infusion of lymphocytes to mediate antitumor, antiviral, or anti-inflammatory effects.
C. June, Roddy S. O’Connor, O. Kawalekar, S. Ghassemi, M. Milone   +4 more
semanticscholar   +1 more source

Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response

Signal Transduction and Targeted Therapy, 2022
Cancers are highly complex diseases that are characterized by not only the overgrowth of malignant cells but also an altered immune response. The inhibition and reprogramming of the immune system play critical roles in tumor initiation and progression ...
Dongrui Wang, Xian Wu, Yingchaun Sun
semanticscholar   +1 more source

Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells

Molecular Oncology, EarlyView.
In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi, Jérome Vialaret, Christophe Hirtz, Catherine Alix‐Panabières   +3 more
wiley   +1 more source

Ly6E on tumor cells impairs anti-tumor T-cell responses: a novel mechanism of tumor-induced immune exclusion

Cancer Immunology, Immunotherapy
Background Lymphocyte antigen 6 complex, locus E (Ly6E) has been initially demonstrated to involve in T cell activity and impair viral infectivity. Recently, high expression levels of Ly6E have been reported in tumor microenvironment (TME) of various ...
Lan Hailin, Chen Yiting, Wu Yue, Li Lijun, Zhang Renlu, Chen Yunhan, Zhu Yanyang, Zhang Qiuyu   +7 more
doaj   +1 more source

Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis

OncoImmunology, 2022
Recombinant-modified vaccinia virus Ankara (rMVA) is known to elicit potent antitumor immune responses in preclinical models due to its inherent ability to activate the innate immune system and the activation of adaptive responses mediated by the ...
Ángela Bella, Leire Arrizabalaga, Claudia Augusta Di Trani, Assunta Cirella, Myriam Fernandez-Sendin, Celia Gomar, Joan Salvador Russo-Cabrera, Inmaculada Rodríguez, José González-Gomariz, Maite Alvarez, Álvaro Teijeira, José Medina-Echeverz, Maria Hinterberger, Hubertus Hochrein, Ignacio Melero, Pedro Berraondo, Fernando Aranda   +16 more
doaj   +1 more source

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

Molecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, Simon P. Gampenrieder, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Michael Hubalek, Katja Schmitz, Zsuzsanna Bago‐Horvath, Andreas Petzer, Sonja Heibl, Ellen Heitzer, Marija Balic, Michael Gnant   +14 more
wiley   +1 more source

Feasibility of radical cardiac‐sparing, treatment planning strategies for patients with locally advanced, non‐small cell lung cancer

Journal of Applied Clinical Medical Physics, Volume 23, Issue 12, December 2022., 2022
Abstract Purpose A set of treatment planning strategies were designed and retrospectively implemented for locally advanced, non‐small cell lung cancer (NSCLC) patients in order to minimize cardiac dose without compromising target coverage goals. Methods Retrospective analysis was performed for 20 NSCLC patients prescribed to 60–66 Gy that received a ...
Joshua P. Kim, Jake Dewalt, Aharon Feldman, Khaled Adil, Benjamin Movsas, Indrin J. Chetty   +5 more
wiley   +1 more source

Melanoma immunotherapy [PDF]

Cancer Biology & Therapy, 2014
Immunotherapy is a cornerstone in the treatment of melanoma, and is intended to modulate the host immunity against the tumor. Immunotherapy can be used in an adjuvant setting, after complete surgical excision in patients with a high risk of disease relapse and as a treatment in advanced (unresectable or metastatic) stages.
SANLORENZO, Martina, Vujic I, Posch C, Dajee A, Yen A, Kim S, Ashworth M, Rosenblum MD, Algazi A, OSELLA ABATE, Simona, QUAGLINO, Pietro, Daud A, Ortiz Urda S.   +12 more
openaire   +4 more sources